Developing New Generation Medicines for Depression and Other Central Nervous System (CNS) Disorders

AV-101, our oral N-methyl-D-aspartate (NMDA) receptor glycine B (GlyB) antagonist, belongs to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators having the potential to treat Major Depressive Disorder (MDD) faster than current FDA-approved antidepressants commonly known as SSRIs and SNRIs, which target the neurotransmitters serotonin and/or norepinephrine, respectively.

Learn About AV-101 AV-101 Mechanism of Action Video

Going Above and Beyond Current Treatment Options

Focused on providing novel solutions for millions of patients with depression and other CNS disorders.

About us

Committed to Developing a New Generation of Oral Antidepressants

AV-101, our oral N-methyl-D-aspartate (NMDA) receptor glycine B (GlyB) antagonist, belongs to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators having the potential to treat depression, including Major Depressive Disorder (MDD), faster than current FDA-approved antidepressants commonly known as SSRIs and SNRIs, which target the neurotransmitters serotonin and/or norepinephrine, respectively. AV-101 is in Phase 2 development, initially for the adjunctive treatment of MDD. ELEVATE is our ongoing Phase 2, randomized, double-blind, multi-center, placebo-controlled clinical trial designed to evaluate the efficacy and safety of adjunctive use of oral AV-101 for MDD in patients with an inadequate response to standard antidepressant therapy with either an FDA-approved selective SSRI or SNRI.

What Makes AV-101 Different?

Going Above and Beyond Current Treatment Options

Focused on providing novel solutions for millions of depression patients with inadequate response to current FDA-approved antidepressants.

Learn More About Ketamine and AV-101

Backed by an Experienced Leadership Team

Our highly experienced Management Team, Board of Directors, and CNS Clinical and Regulatory Advisory Board have a proven track record of developing innovative medicines to treat a wide range of CNS diseases and disorders.

Meet Our Team

Stock Information

View Detailed Stock Info
Nasdaq: VTGN Symbol
Price
Change
Volume
Day Range
52 Week Range

Corporate Presentation

Fact Sheet

For Investors

Email Updates

Be the first to receive news, events & updates Sign Up